Article Text

Download PDFPDF
Anlotinib in recurrent or metastatic endometrial cancer
  1. Qingli Cui1,
  2. Yuefeng Mao2,
  3. Yanhui Hu1,
  4. Dongyang Ma1 and
  5. Huaimin Liu1
  1. 1Department of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
  2. 2Department of Medical Oncology, Second People's Hospital of Pingdingshan, Pingdingshan, Henan, China
  1. Correspondence to Dr Huaimin Liu, Department of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450003, China; huaiminliu{at}sina.com

Abstract

Objective For recurrent or metastatic endometrial cancer after second-line treatment, therapeutic options are limited. Anlotinib is a new multi-targeted tyrosine kinase inhibitor of tumor angiogenesis and growth. The aim of this study was to explore the efficacy and safety of anlotinib in patients with recurrent or metastatic endometrial cancer.

Methods Patients with recurrent or metastatic endometrial cancer who received anlotinib or anlotinib plus pembrolizumab after second-line treatment between July 2017 and October 2020 were analyzed. Objective response rate, disease control rate, progression-free survival, overall survival, and safety were evaluated.

Results A total of 56 patients were analyzed. The median age was 62 years (range 42–80). The median treatment of anlotinib was 5.9 cycles (range 2–21). The overall objective response rate was 42.9%, and the disease control rate was 75%. 44 (78.6%) patients received anlotinib monotherapy and 12 (21.2%) patients received anlotinib plus pembrolizumab. The objective response rate was 40.9% versus 50% (p=0.52) and the disease control rate was 72.7% versus 83.3% (p=0.59) in the monotherapy group and the combination therapy group, respectively. The median progression-free survival and overall survival from initiation of anlotinib therapy was 6 months (95% CI 4.89 to 7.11) and 13.3 months (95% CI 9.94 to 16.61), respectively. On multivariable Cox analysis, age (>60 vs ≤60 years) was an independent impact factor for both progression-free survival and overall survival, while prior lines of treatment (2 lines vs ≥3 lines) was an independent predictor of progression-free survival. The incidences of grade 3/4 adverse events were hypertension (10.7%), fatigue (7.1%), hand-foot syndrome (7.1%), proteinuria (3.6%), sore throat (3.6%), and hypothyroidism (3.6%).

Conclusion Anlotinib is effective and well tolerated in patients with recurrent or metastatic endometrial cancer. It may be considered a choice for patients younger than 60 years and who have had <3 lines of treatment.

  • Endometrial Neoplasms

Data availability statement

Data are available upon reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request.

View Full Text

Footnotes

  • Contributors QC and HL designed the study, contributed to data collection from medical files and wrote the article. YM performed the statistical analysis. DM and YH performed the data analysis, interpretation, and revised the final manuscript. HL is responsible for the overall content as guarantor.

  • Funding This project was funded in 2020 by the Joint Co-construction Project (LHGJ20200162) in Medical Science and Technology Research Plan in Henan province.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.